Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Investor Day (October 2007)
11 slides from Teva Pharmaceutical Industries's investor day presentation, Oct 15, 2007
Slide 1: Global Innovative R&D
Irit Pinchasi, PhD VP Global Innovative R&D October 2007 1 Forward-Looking Statements TODAY’S PRESENTATION CONTAINS FORWARD LOOKING STATEMENTS WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS ARE BASED ON CURRENT EXPECTATIONS AND INVOLVE A NUMBER OF KNOWN AND UNKNOWN
Slide 2: Agenda; Innovative Pipeline: Operational Strategy
Agenda • Introduction • Multiple Sclerosis - Copaxone® 40 mg - Laquinimod • Parkinson’s Disease - Azilect for PD Modification • ALS - Glatiramer Acetate - Talampanel • Oncology - CT-011 3 Innovative Pipeline : Operational Strategy • Sourcing both pre-clinical and early clinical products globally, in
Slide 3: Criteria for Product Selection; Global IR&D Organization
Criteria for Selection of Products for Development • Niche Indications with significant unmet medical needs ( multiple sclerosis and other auto-immune diseases; neurological diseases; oncology) • High leadership potential: market share; first - line treatment, peak sales…. • High degree of innovatio
Slide 4: Development Pipeline (Oct. 07); FORTE Phase III Study
Development Pipeline (Oct. 07) Laquinimod (MS) Copaxone Copaxone Copaxone 40mg (CIS/MS ) (MS) (MS) Edratide Edratide (Lupus (Systemic Nephritis) Lupus) Submission Talampanel Copaxone Rasagiline 40mg Azilect Azilect (ALS ) (AD) (PD/DM) (PD) (ALS) CT-011 Talampanel CT-011 (Hematol. StemEx (Solid (GBM)
Slide 5: Copaxone 40mg Opportunity; Laquinimod Global Phase III Plan
Copaxone® 40mg Opportunity • The 40 mg dose of Copaxone® is potentially an improved product with: – Better efficacy – Rapid onset of action – Good safety and tolerability • The excellent safety profile makes 40 mg dose good candidate for combination therapies • Based on current understanding of the
Slide 6: Laquinimod Opportunity; ADAGIO Phase III Study of Azilect
Laquinimod Opportunity • Laquinimod is an oral product with a rapid onset of action • Effective as monotherapy and may be a good candidate for combination therapies • Unlike other oral drugs under development for Relapsing MS, Laquinimod does not seem to induce general immune suppression and, theref
Slide 7: Azilect Opportunity; Copaxone Clinical Experience in ALS
Azilect® Opportunity • Azilect® is effective as monotherapy for treating symptoms in early Parkinson’s Disease patients while significantly improving quality of life • Offers additional therapeutic benefits in patients already optimized on Levodopa and other Parkinson’s Disease therapies • Significa
Slide 8: GoALS Phase IIb Study; Glatiramer Acetate 40mg Opportunity
GoALS - A Phase IIb Study Of GA in ALS Objectives Show efficacy of Glatiramer Acetate over placebo (+riluozole) Study design Randomized, double-blind, placebo-controlled, parallel-group Patients 360 ALS patients Treatment duration 12 months Dosing regimen 40 mg GA, once daily, s.c. injection Primary
Slide 9: Talampanel for ALS; Phase IIb Study
Talampanel for ALS • Selective, noncompetitive AMPA antagonist • Orally active, with a novel mechanism of action • Shows activity in various neuroprotection, dyskinesia, and autoimmune encephalomyelitis models • Positive trends of activity in ALS patients in an early Phase II study 17 A Global Phase
Slide 10: Talampanel Opportunity in ALS; CT-011 Overview
Talampanel Opportunity in ALS • An oral treatment • A disease with a very high unmet medical need • A reasonable safety and tolerability profile at the selected dose • Orphan Drug Designation/Fast Track Next Milestone: Go to Phase III : Q2/2010 19 CT-011 Overview • A humanized MAb that exerts anti-t
Slide 11: Phase IIb Study of CT-011 in Lymphoma; CT-011 Opportunity
A Phase IIb Study Of CT-011 in Lymphoma Patients Objectives Show efficacy of CT-011 in Lymphoma patients Study design Open-label, single arm , multi-center ( US and Israel) Patients 68 lymphoma patients, 60-75 days post autologous BMT Treatment duration Follow-up of patients up to 16 months after 1s
Teva Pharmaceutical Industries — Investor Day (October 2007) on 6ix